Funder
National Natural Science Foundation of China
Natural Science Foundation of Shandong Province of China
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Malemud CJ (2018) The role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis 10(11):225. https://doi.org/10.1177/1759720X18776224
2. Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S (2016) The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34(2):318–328
3. Palmroth M, Kuuliala K, Peltomaa R, Virtanen A, Kuuliala A, Kurttila A, Kinnunen A, Leirisalo-Repo M, Silvennoinen O, Isomäki P (2021) Tofacitinib suppresses several JAK-STAT pathways in rheumatoid arthritis in vivo and baseline signaling profile associates with treatment response. Front Immunol 12:738481. https://doi.org/10.3389/fimmu.2021.738481
4. Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, Lazariciu I, Wang L, Cohen S (2019) Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 21(1):89
5. Harrington R, Harkins P, Conway R (2023) Janus kinase inhibitors in rheumatoid arthritis: An update on the efficacy and safety of tofacitinib, baricitinib and upadacitinib. J Clin Med 12(20):6690. https://doi.org/10.3390/jcm12206690